Formononetin-Celecoxib Conjugate as Matrix Metalloproteinase 9 Inhibitor for Osteoarthritis Therapy

Area of Science:

• Drug Discovery and Development
• Computational Chemistry
• Pharmacology

Background:

• Osteoarthritis (OA) poses a significant health challenge, necessitating novel therapeutic strategies.
• Current treatments for OA often have limitations, driving the search for new medicinal agents.
• Formononetin and Celecoxib are known compounds with potential therapeutic properties.

Purpose of the Study:

• To synthesize and characterize a novel Formononetin-Celecoxib Conjugate.
• To evaluate the in vitro and in vivo efficacy of the conjugate for osteoarthritis.
• To ascertain its potential as a therapeutic agent for OA.

Main Methods:

• Computational analyses including molecular docking were performed on curated phytoconstituents and drugs.
• The Formononetin-Celecoxib Conjugate was synthesized and characterized using spectroscopic methods.
• In vitro assays (MTT, ELISA) and in vivo studies using an MIA-induced OA mouse model were conducted.

Main Results:

• The conjugate exhibited high binding affinity for MMP-9.
• In vitro studies showed the conjugate was non-toxic and reduced MMP-9 expression.
• In vivo, the conjugate attenuated paw swelling and prevented weight loss in OA mice, demonstrating significant therapeutic benefits.

Conclusions:

• The Formononetin-Celecoxib Conjugate demonstrates anti-inflammatory and disease-modifying potential for OA.
• MMP-9 inhibition by the conjugate suggests translational relevance for human OA treatment.
• This integrated computational and experimental approach advances precision medicine for OA management.